Table 3.
UVB-induced minimal erythema dose, time of exposure and skin characteristics determined before and after PomX, PomJ and placebo intervention.
| Pom Juice (n = 24) | Pom extract (n = 25) | Placebo (n = 25) | |
|---|---|---|---|
| Compliance F (%) | 96.3 ± 5.1 | 97.5 ± 3.9 | 98.9 ± 2.1 |
| MED BL (mJ/cm2) | 383.6 ± 95.8 | 396.8 ± 83.6 | 384.2 ± 105.6 |
| MED F (mJ/cm2) | 418.3 ± 113.1* | 429.6 ± 81.8* | 367.2 ± 90.2 |
| Time BL (sec) | 175.5 ± 42.9 | 193.7 ± 46.7 | 185.6 ± 52.5 |
| Time F (sec) | 199.1 ± 58.6 | 203.6 ± 49.0 | 177.2 ± 43.6 |
| Melanin index BL (RU) | 264.5 ± 212.6 | 242.7 ± 91.1 | 202.2 ± 75.4 |
| Melanin index F (RU) | 195.0 ± 63.9 | 219.6 ± 61.0 | 198.9 ± 67.4 |
| Sebum BL (µg/cm2) | 17.0 ± 19.7 | 14.8 ± 17.5 | 22.1 ± 36.8 |
| Sebum F (µg/cm2) | 15.3 ± 24.4 | 15.2 ± 18.2 | 26.9 ± 37.7 |
| Hydration BL (RU) | 41.8 ± 14.4 | 36.4 ± 12.6 | 41.9 ± 14.5 |
| Hydration F (RU) | 38.7 ± 9.8 | 41.4 ± 11.4 | 40.9 ± 10.8 |
Data are mean ± SD, n = 24–25. BL = baseline, F = final, RU = relative unit. ANCOVA model was used to compare outcomes adjusted for baseline value. *p < 0.05. Minimal erythema dose (MED); baseline BL; final (F).